Biomarkers of pituitary neoplasms: A review (Part II)

Neurosurgery

Volumn 67, Issue 6, 2010, Pages 1790-1798

  Salehi, Fateme ^a   Agur, Anne ^b   Scheithauer, Bernd W ^c   Kovacs, Kalman ^a   Lloyd, Ricardo V ^c   Cusimano, Michael ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Cyclooxygenase 2; Fibroblast growth factor; Galectin 3; Matrix metalloproteinase; p53; Pituitary tumors; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GALECTIN 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN P21; PROTEIN P27; PROTEIN P53; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CAPILLARY DENSITY; CELL ADHESION; CELL AGING; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MARKER; GENE; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; MICROVASCULAR DENSITY; NONHUMAN; PITUITARY TUMOR TRANSFORMING GENE; PRIORITY JOURNAL; REVIEW; SENESCENCE; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; BIOLOGICAL MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; PITUITARY NEOPLASMS;

EID: 78650516354     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3181faa680     Document Type: Review

References (79)

1. Bamberger CM, Fehn M, Bamberger AM, et al. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol. 1999;140(3):250-255.
2. Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, Beliveau R. Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery. 1999;45(6):1432-1440; discussion 1440-1431.
3. Fukui S, Nawashiro H, Otani N, et al. Vascular endothelial growth factor expression in pituitary adenomas. Acta Neurochir Suppl. 2003;86:519-521.
4. Hentschel SJ, McCutcheon E, Moore W, Durity FA. p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 2003;30(3):215-219.
5. Hiyama H, Kubo O, Kawamata T, Ishizaki R, Hori T. Expression of cyclin kinase inhibitor p21/WAF1 protein in pituitary adenomas: correlations with endocrine activity, but not cell proliferation. Acta Neurochir (Wien). 2002;144(5):481-488.
6. Bloomer CW, Kenyon L, Hammond E, et al. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas. Am J Clin Oncol. 2003;26(4):S75-80.
7. Jin L, Qian X, Kulig E, et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol. Aug 1997;151(2):509-519.
8. Onguru O, Casey MB, Kajita S, Nakamura N, Lloyd RV. Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review. Endocr Pathol. Winter 2005;16(4):253-277.
9. Thodou E, Argyrakos T, Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens). 2007;6(3):227-232.
10. Wierinckx A, Auger C, Devauchelle P, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007;14(3):887-900.
11. Decock J, Paridaens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet. 2008;73(3):197-211.
12. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
13. Yamada S, Takada K. Angiogenesis in pituitary adenomas. Microsc Res Tech. 2003;60(2):236-243.
14. Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol. 1995;6(2):115-124.
15. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. J Endocrinol. 2000;165(2):475-481.
16. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 2001;438(6): 595-602.
17. Viacava P, Gasperi M, Acerbi G, et al. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest. 2003;26(1):23-28.
18. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer. 2000;82(8):1441-1445.
19. Niveiro M, Aranda FI, Peiro G, Alenda C, Pico A. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol. 2005;36(10):1090-1095.
20. Pan LX, Chen ZP, Liu YS, Zhao JH. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol. 2005;74(1):71-76.
21. Arita K, Kurisu K, Tominaga A, et al. Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma. Hiroshima J Med Sci. 2004;53(2):23-27.
22. McCabe CJ, Boelaert K, Tannahill LA, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab. 2002;87(9):4238-4244.
23. Iuchi T, Saeki N, Osato K, Yamaura A. Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien). 2000;142(12):1345-1351.
24. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol. 1999;10(3):229-235.
25. Korsisaari N, Ross J, Wu X, et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res. 2008;14(1):249-258.
26. Fukui S, Otani N, Nawashiro H, et al. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol. 2002;19(1):23-29.
27. Qian ZR, Sano T, Asa SL, et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab. 2004;89(4):1904-1911.
28. McCabe CJ, Khaira JS, Boelaert K, et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf). 2003;58(2):141-150.
29. Suzui H, Takahashi JA, Fukumoto M, et al. Immunohistochemical study for basic fibroblast growth factor and fibroblast growth factor receptor I in pituitary adenomas. Neurosci Lett. 1994;171(1-2):192-196.
30. Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology. 1994;135(5): 2012-2021.
31. Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z. Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr Pathol. 1996;7(1):63-70.
32. LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab. 1996;81(2):656-662.
33. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. Endocr Pathol. 2004;15(1):17-27.
34. Theodoropoulou M, Arzberger T, Gruebler Y, et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol. 2004;183(2):385-394.
35. Kim K, Yoshida D, Teramoto A. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol. 2005;16(2):115-121.
36. Vidal S, Horvath E, Kovacs K, Kuroki T, Lloyd RV, Scheithauer BW. Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in pituitary tumours. Histol Histopathol. 2003;18(3):679-686.
37. Zhang X,Horwitz GA,Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84(2):761-767.
38. Yoshida D, Kim K, Yamazaki M, Teramoto A. Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas. Endocr Pathol. 2005;16(2):123-131.
39. Vidal S, Kovacs K, Bell D, Horvath E, Scheithauer BW, Lloyd RV. Cyclooxygenase- 2 expression in human pituitary tumors. Cancer. 2003;97(11):2814- .2821.
40. Liu W, Kunishio K, Matsumoto Y, Okada M, Nagao S. Matrix metalloproteinase- 2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci. 2005;12(7):791-794.
41. Hussaini IM, Trotter C, Zhao Y, et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol. 2007;170(1):356-365.
42. Gong J, Zhao Y, Abdel-Fattah R, et al. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary. 2008;11(1):37-48.
43. Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Ludecke DK, Saeger W. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol. 2003;106(5):471-478.
44. Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab. 2000;85(8):2931-2935.
45. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T. Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir (Wien). 1996;138(4):390-395.
46. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir (Wien). 1996;138(12):1442-1448.
47. Yamada S, Ohyama K, Taguchi M, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007;61(3):580-584; discussion 584-585.
48. Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu JI. Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/ or invasive Neurosurgery. 2001;49(4):857-862; discussion 862-853.
49. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol. 1997;150(2):401-407.
50. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154(2):313-323.
51. Scheithauer BW, Gaffey TA, Lloyd RV, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59(2):341-353; discussion 341-353.
52. Zhao D, Tomono Y, Nose T. Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien). 1999;141(2):187-192.
53. Nakabayashi H, Sunada I, Hara M. Immunohistochemical analyses of cell cyclerelated proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem. 2001;49(9):1193-1194.
54. Ikeda H, Yoshimoto T, Shida N. Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer. 1997;76(9):1119-1123.
55. Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S, Shimon I. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol. 1998;157(2):337-341.
56. Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002;87(6):2635-2643.
57. Chesnokova V, Zonis S, Kovacs K, et al. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA. 2008;105(45):17498-17503.
58. Neto AG, McCutcheon IE, Vang R, Spencer ML, Zhang W, Fuller GN. Elevated expression of p21 (WAF1/Cip1) in hormonally active pituitary adenomas. Ann Diagn Pathol. 2005;9(1):6-10.
59. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-3202.
60. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38(4):765-770; discussion 770-761.
61. Ozer E, Canda MS, Ulukus C, Guray M, Erbayraktar S. Expression of Bcl-2, Bax and p53 proteins in pituitary adenomas: an immunohistochemical study. Tumori. 2003;89(1):54-59.
62. Suliman M, Royds J, Cullen D, et al. Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf). 2001;54(3):317-325.
63. Vidal S, Horvath E, Kovacs K, Scheithauer BW, Lloyd RV, Kontogeorgos G. Ultrastructural features of apoptosis in human pituitary adenomas. Ultrastruct Pathol. 2001;25(2):85-92.
64. Ibrahim AE, Pickering RM, Gawne-Cain ML, King S, Lees PD, Ellison DW. Indices of apoptosis and proliferation as potential prognostic markers in nonfunctioning pituitary adenomas. Clin Neuropathol. 2004;23(1):8-15.
65. Kulig E, Jin L, Qian X, et al. Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol. 1999;154(3):767-774.
66. Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A. Apoptosis in human pituitary adenomas: a morphologic and in situ end-labeling study. Mod Pathol. 1997;10(9):921-926.
67. Losa M, Barzaghi RL, Mortini P, et al. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas. Am J Pathol. 2000;156(1):245-251.
68. Sambaziotis D, Kapranos N, Kontogeorgos G. Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas. Pituitary. 2003;6(3):127-133.
69. Green VL, White MC, Hipkin LJ, Jeffreys RV, Foy PM, Atkin SL. Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Eur J Endocrinol. 1997;136(4):382-387.
70. Kontogeorgos G, Kapranos N, Thodou E, Sambaziotis D, Tsagarakis S. Immunocytochemical accumulation of p53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis. Pituitary. 1999;1(3-4):207-212.
71. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63(9):2251-2255.
72. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11(4):433-441.
73. Chen L, Liu YS, Wang LS, et al. [Expression of pituitary tumor transforming gene, endostatin, and basic fibroblast growth factor mRNAs in invasive pituitary adenomas]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2004;29(6): 651-653, 666.
74. Filippella M, Galland F, Kujas M, et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf). 2006;65(4):536-543.
75. Hunter JA, Skelly RH, Aylwin SJ, et al. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol. 2003;148(2):203-211.
76. Saez C, Japon MA, Ramos-Morales F, et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene. 1999;18(39): 5473-5476.
77. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285(5426):418-422.
78. Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol. 2006;17(2):143-153.
79. Ruebel KH, Leontovich AA, Jin L, et al. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine. 2006;29(3):435-444.